American Society of Hematology

Figure 5

$Figure 5. Subcellular localization of CD22 in D1-7 cells. The cells were similarly treated as in Figure 4. The cell lysates were fractionated by sucrose density-gradient ultracentrifugation. The lipid rafts were collected from the interface of 5% to 30% sucrose, and soluble fractions were from 40% sucrose at the bottom of the tubes. Distribution of CD22 and phospho-CD22 in the soluble fractions and lipid rafts were analyzed by Western blotting with HRP-anti-CD22 mAb (top 4 panels) and HRP-4G10 (bottom 4 panels), respectively. Labels CD22 and pCD22 on the right indicate the positions of CD22 and phospho-CD22, respectively. Lanes 3 and 4 are samples treated with hA20IgG-(LL2scFv)2 (labeled as α-CD20/22-L) and TF3 (labeled as α-CD20/22-DNL), respectively. Lane 8 is the sample treated with α-IqM Ab.$

Subcellular localization of CD22 in D1-7 cells. The cells were similarly treated as in Figure 4. The cell lysates were fractionated by sucrose density-gradient ultracentrifugation. The lipid rafts were collected from the interface of 5% to 30% sucrose, and soluble fractions were from 40% sucrose at the bottom of the tubes. Distribution of CD22 and phospho-CD22 in the soluble fractions and lipid rafts were analyzed by Western blotting with HRP-anti-CD22 mAb (top 4 panels) and HRP-4G10 (bottom 4 panels), respectively. Labels CD22 and pCD22 on the right indicate the positions of CD22 and phospho-CD22, respectively. Lanes 3 and 4 are samples treated with hA20IgG-(LL2scFv)₂ (labeled as α-CD20/22-L) and TF3 (labeled as α-CD20/22-DNL), respectively. Lane 8 is the sample treated with α-IqM Ab.

This Feature Is Available To Subscribers Only